Invasive Hemodynamic Monitoring in Cardiogenic Shock
Definition
The use of a pulmonary artery catheter (PAC) and derived hemodynamic parameters to characterize the severity, phenotype, and trajectory of cardiogenic shock — guiding device escalation, pharmacological titration, and weaning decisions.
Key Concepts
Cardiac Power Output — Strongest Hemodynamic Predictor
- CPO formula: CPO (watts) = (MAP × CO) / 451 sources/mcs-jic-2023 (high)
- CPO is the single strongest hemodynamic predictor of in-hospital mortality in CS (SHOCK trial registry) — superior to CI or MAP in isolation sources/mcs-ehj-2014 (medium)
- CPO <0.6 W = critical threshold; associated with high mortality risk
- CPO/lactate stratification at 12–24h (decision rule): sources/mcs-jic-2023 (high)
- CPO <0.6 W + lactate >4 mmol/L → device escalation
- CPO >0.6 W + lactate <4 mmol/L → consider weaning catecholamines and tMCS
Temporal Limits of Hemodynamic Indices
- After the first 24h in AMI-CS: MODS severity (APACHE II / SAPS II) and SIRS biomarkers (IL-6, RAGE) predict mortality more accurately than hemodynamic indices sources/mcs-ehj-2014 (medium)
- CI alone is unrelated to survival beyond 24h in AMI-CS — do not use CI as a standalone late-phase prognostic marker sources/mcs-ehj-2014 (medium)
- Early hemodynamic assessment within 12 hours is associated with improved clinical outcomes sources/cardiogenic-shock-acc-2025 (very high)
PAC Use — Current Evidence
- No CS-specific RCT for PAC (PACCS trial ongoing) sources/cardiogenic-shock-acc-2025 (very high)
- PAC use associated with improved outcomes in retrospective and registry data; ESCAPE trial inapplicable (decompensated HF, not CS)
- Complete hemodynamic profiling (vs incomplete/none) → lower in-hospital mortality sources/mcs-jic-2023 (high)
Congestion Profiles
Three invasive hemodynamic phenotypes, each with distinct prognostic implications sources/mcs-jic-2023 (high):
- LV-dominant: PCWP >15 mmHg, normal or low RA pressure
- RV-dominant: RA pressure >15 mmHg, RA/PCWP ratio >0.63–0.86, normal or near-normal PCWP; elevated PAPi sensitivity for this phenotype
- Biventricular: both PCWP >15 mmHg and RA pressure elevated — adverse prognosis; more common in non-AMI CS; RV involvement present in 44% of AMI-CS
Recovery Markers
- Pulse pressure reappearance under VA-ECMO: prerequisite before initiating weaning sequence sources/mcs-jic-2023 (high)
- LVOT-VTI increase on echocardiography: LV recovery marker during Impella weaning
- ETCO2: emerging non-invasive recovery detection metric
- Pulsatility index (PI) on Impella: native cardiac contraction marker; rising PI indicates LV recovery
Key Hemodynamic Thresholds for Device Weaning
From the structured ECPELLA three-step weaning protocol sources/mcs-jic-2023 (high):
- VA-ECMO decannulation criteria: RA pressure <15 mmHg AND PAPi ≥1.0 (minimum flow 1–1.5 L/min before decannulation)
- Impella weaning criteria: PAWP <20 mmHg AND CPO ≥0.6 W (minimum P-level 2)
- See concepts/Pulmonary-Artery-Pulsatility-Index for PAPi details
HF-CS vs AMI-CS — Hemodynamic Phenotype Distinction
- AMI-CS: abrupt myocardial dysfunction → rapid deterioration; hypoperfusion (elevated lactate, AKI, hepatic dysfunction) is early and clinically apparent (sources/rhc-hf-jacchf-2024, rating: high)
- HF-CS (progressive HF cardiogenic shock): insidious low CO with chronic adaptation → hemodynamic derangements are often more severe than AMI-CS, but end-organ function is preserved and serum lactate is normal at presentation; patients may appear relatively stable despite profound hemodynamic compromise (sources/rhc-hf-jacchf-2024, rating: high)
- Clinical consequence: HF-CS patients are systematically under-triaged without invasive hemodynamic assessment; RHC unmasks the severity and guides early escalation to inotropes, temporary MCS, or advanced therapies (sources/rhc-hf-jacchf-2024, rating: high)
- Hemodynamic monitoring targets in CS: RAP 8–12 mmHg, PCWP ≤15 mmHg, CI ≥2.2 L/min/m² (sources/rhc-hf-jacchf-2024, rating: high)
- CPO formula: include RAP in calculation when elevated (frequently so in CS) to avoid error — CPO (W) = (MAP × CO) / 451 (sources/rhc-hf-jacchf-2024, rating: high)
Contradictions / Open Questions
- No RCT for PAC in CS: all benefit data observational/registry; PACCS trial ongoing; recommendation to use PAC is expert consensus sources/cardiogenic-shock-acc-2025 (very high)
- Optimal MAP target: >65 mmHg standard; ongoing RCT testing 55 vs 65 mmHg — lower target may reduce LV afterload but risks organ hypoperfusion
- CI as a late marker: CI unrelated to survival after 24h in AMI-CS; organ failure indices overtake hemodynamic parameters as prognostic drivers — clinical implications for PAC-guided management beyond 24h are unclear sources/mcs-ehj-2014 (medium)
Connections
- Related to concepts/Cardiogenic-Shock
- Related to concepts/Temporary-Mechanical-Circulatory-Support
- Related to concepts/ECPELLA
- Related to concepts/SCAI-Shock-Classification
- Related to concepts/Pulmonary-Artery-Pulsatility-Index
- Related to concepts/Right-Heart-Catheterization
- Related to concepts/Cardiac-Output-Measurement — thermodilution CO measurement via PAC; error sources affecting CPO accuracy in CS